[Feladilimab] is under development [by the pharmaceutical company GSK] for the treatment of [malignant pleural mesothelioma], advanced solid tumors including non-small cell lung cancer, squamous non-small cell lung cancer, bladder cancer, cervical cancer, esophageal, urothelial cancer, clear renal cell carcinoma, head and neck cancer squamous cell carcinoma including oral, pharyngeal and larynx cancer, hypopharyngeal cancer, paranasal sinus and nasal cavity cancer, [… as well as] squamous and cutaneous melanoma, metastatic prostate cancer, castration-resistant prostate cancer, metastatic colorectal cancer and recurrent head and neck cancer squamous cell carcinoma, oral cavity (mouth) cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, HPV associated cancer. [Feladilimab] is administered intravenously as an infusion. It acts by targeting inducible T-cell costimulator, ICOS.
[Feladilimab] was also under development for the treatment of squamous cell carcinoma, non-small cell lung cancer, multiple myeloma, squamous non-small cell lung cancer (third line), and non-squamous non-small cell lung cancer.
Asbestos-Mesothelioma Case Evaluation
Free. Confidential. No Obligation.